CytomX Therapeutics enters strategic collaboration with Amgen

CytomX Therapeutics Inc. (Nasdaq: CTMX) entered a strategic collaboration agreement with Amgen Inc. (Nasdaq: AMGN) to jointly develop a CytomX Probody T-cell engaging bispecific against the Epidermal Growth Factor Receptor. Shares of CytomX Therapeutics leaped $4.09 to close at $23.09 while Amgen stock climbed $1.36 to close at $188.59.